Now that the Abbott Freestyle Libre has received FDA clearance, Abbott and Dexcom will be forced into tight competition in the US market. On Dexcom’s third quarter call, CEO Kevin Sayer spent some ...
Dexcom reported second-quarter results on Friday, July 26. Management lowered its forward revenue outlook because of unexpected challenges with its new glucose monitoring device. Dexcom's main ...
As of this week, consumers can order Dexcom Inc.’s Stelo continuous glucose monitor (CGM) online without a prescription, making it the first to hit the market. Dexcom will have competition soon, ...
DexCom has enormous runway for growth, not just in its home market - the U.S., but internationally as well. Manufacturing efficiencies could support their international ambitions while supporting ...
Insulin pump maker Insulin announced partnerships yesterday with two of the leading continuous glucose monitor companies, Abbott and Dexcom. Both involve the Insulet’s Omnipod Horizon Automated ...
Please confirm that you would like to log out of Medscape. If you log out, you will be required to enter your username and password the next time you visit. Log out ...
Shares of the medical device maker DexCom (NASDAQ: DXCM) shot about 50% higher in October. Unfortunately, the stock is still around 25% below the peak it reached in late 2021. Investors who have seen ...
DexCom, Inc. DXCM reported second-quarter 2025 results that highlighted robust top-line growth, continued progress in expanding access and meaningful product innovation. Revenues grew 15% year over ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results